24/7 Market News Snapshot 08 October, 2025 – TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ)

October 8, 2025

DENVER, Colo., 08 October, 2025 (www.247marketnews.com) – (NASDAQ:RNAZ) are discussed in this article.
TransCode Therapeutics, Inc. is experiencing a notable surge in its stock price amidst key developments that position the company as a leader in oncology innovation. Following the announcement of its acquisition of Polynoma LLC, a biotechnology firm specializing in immuno-oncology, TransCode’s stock has seen significant volatility, trading up by 28.28% to reach $15.68 after opening at $18.71. This acquisition strategically enhances TransCode’s pipeline, particularly with Polynoma’s candidate, seviprotimut-L, which is poised for Phase 3 trials targeting melanoma patients.

The recent $25 million investment from CK Life Sciences is intended to bolster the clinical development of TransCode’s lead microRNA therapeutic, TTX-MC138, further solidifying its commitment to advancing innovative cancer treatments. The convergence of microRNA and vaccine technologies heralds a transformative opportunity for the company, as it seeks to deliver state-of-the-art solutions for patients facing challenging metastatic diseases.

In tandem with these developments, TransCode has reaffirmed its leadership structure by appointing Philippe Calais, PharmD, PhD, as the Chief Executive Officer while he maintains his role as Chairman of the Board. Tom Fitzgerald continues as Chief Financial Officer, ensuring stability during this critical transition. In addition, Elizabeth Czerepak, MBA, joins the Board as an independent member and Chairperson of the Audit Committee, bringing valuable insights to the leadership team.

As market interest grows alongside TransCode’s ambitious objectives, the company is poised for a significant evolution in its operational and therapeutic framework, reinforcing its dedication to pioneering solutions in cancer care. The integration of Polynoma’s technology and expertise is expected to establish a robust platform for future innovations, ultimately striving to improve treatment outcomes for patients in need.

Related news for (RNAZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.